FTP-501

FTP-501 is a preclinical-stage drug candidate being developed by **Fastox Pharma**, a Swiss biotechnology company. The drug is intended for the treatment of **skin diseases** and **musculoskeletal disorders**. FTP-501 is part of Fastox's pipeline that leverages a proprietary platform to optimize the performance of **botulinum toxins** (BoNT). Specifically, the candidate is designed to provide a long-lasting therapeutic effect, potentially through a novel formulation or the inclusion of an enhancer that modulates the activity of botulinum toxin type A. By targeting the neuromuscular junction or sensory pathways in the skin, FTP-501 aims to address conditions where prolonged muscle relaxation or sensory modulation is clinically beneficial. While specific details regarding its exact molecular composition remain proprietary, the drug is part of a broader effort to expand the therapeutic utility of botulinum toxins beyond aesthetic applications.